Clinical Comprehensive Evaluation of Neuroprotective Drugs for Acute Ischemic Stroke
ConditionAcute Ischemic Stroke
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorQianfoshan Hospital
About this trial
This study conducted a comprehensive evaluation of commonly used neuroprotective agents in acute ischemic stroke, assessing their real-world value across six dimensions: safety, efficacy, cost-effectiveness, innovativeness, appropriateness, and accessibility. Employing a prospective observational design, it primarily investigates the association of edaravone and dexrazoxane with clinical outcomes in patients with mild-to-moderate stroke, with subgroup analyses performed according to Trial of Org 10172 in Acute Stroke Treatment （TOAST ）classification.
Eligibility criteria
Qualifiers
1: Age≥18
Disqualifiers
1: A head CT or MRI scan indicates the presence of intracranial hemorrhagic disease
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Locations
Sponsors and collaborators
Source ClinicalTrials.gov